索拉非尼治疗晚期肾癌期间引发高血压的分析

摘要

目的：探讨晚期肾癌患者行索拉非尼治疗期间高血压发生率，进而总结降压治疗对索拉非尼疗效的预测关系。方法将我院接收的28例晚期肾癌患者作为研究对象，均给予其索拉非尼治疗，计算患者用药期间高血压发生率，总结其发生率与索拉非尼疗效之间的关系。结果本组28例患者经治疗后，治疗总有效率为82.1%，其中8例（占比为28.6%）见高血压，对患者行药物治疗与生活指导后，血压均稳定，未见索拉非尼停药或减量病例；高血压发生率与索拉非尼疗效关系比较并无显著差异（P＜0.05）。结论晚期肾癌患者行索拉非尼治疗期间的高血压发生率较高，经治疗后血压均可控，且高血压发生率大小与索拉非尼疗效二者之间并无直接关系。%ObjectiveTo study the hypertension incidence of patients with advanced kidney cancer accepted sorafenib treatment, and then summarize the curative effect of antihypertensive treatment on sorafenib predict relationship.Methods 28 cases of our hospital to receive advanced kidney cancer patients as the research object, have given the sorafenib treatment, patients during hypertension incidence, summarize the occurrence and the relationship between the sorafenib curative effect.Results 28 patients after treatment, the total effective rate was 82.1%, of which 8 cases (28.6%), high blood pressure, for patients after drug treatment and life guidance, blood pressure stable, did not see sorafenib withdrawal or decrement case. The incidence of hypertension compared with sorafenib curative effect relationship and there was no signiifcant difference (P<0.05).Conclusion Patients with advanced kidney cancer line sorafenib during treatment of a greater incidence of hypertension, blood pressure after treatment were controlled, and the incidence of hypertension size and sorafenib curative effect, there is no direct relationship between the two.